Prazosin for the treatment of Obsessive Compulsive Disorder: An open label, fixed dose add-on study.

Prazosin for the treatment of Obsessive Compulsive Disorder: An open label, fixed dose add-on study. - Prazosin for therapy resistant OCD.

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON32256

Enrollment

Registered

2008-05-27

Start date

2008-03-01

Completion date

Unknown

Last updated

2024-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

obsessive compulsive disorder/ compulsion

Interventions

Prazosin will be administered at the maximum tolerable dosage in addition to an SRI for 12 weeks.

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: DSM IV diagnosis obsessive-compulsive disorder Y-BOCS score > 16 Therapy resistance (no response to at least 1 previous SRI treatment) Male and female, aged 18-70 years negative pregnancy test Written informed consent

Exclusion criteria

Exclusion criteria: Presence of major depression (HDRS>15), bipolar disorder, schizophrenia or any other psychotic condition, tic disorder, substance related disorder during the past 6 months, epilepsy, or any structural CNS disorder or stroke within the last year. Evidence of clinically significant and unstable somatic abnormalities. Patients at risk for suicide Multiple serious drug allergies or known allergy for the trial compounds Use of antipsychotics during 6 months before the screening visit Use of any other psychotropic drug during 6 months before the screening visit Cognitive and behavioural treatment 3 months prior to the screening visit Use of drugs that interact with prazosin: diuretic, other antihypertensive agents, regular use of alcohol.

Design outcomes

Primary

Measure	Time frame
Change in Yale Brown obsessive-compulsive scale (Y-BOCS) and the number of responders (at least 25% change on the Y-BOCS and final CGI rating of much improved or *very much improved for two consecutive times).	—

Secondary

Measure	Time frame
Changes on following rating scales: CGI: clinical global impression scale BABS: Brown assessment of beliefs scale HDRS: Hamilton depression rating scale HAS: Hamilton anxiety rating scale PADUA INVENTORY: measuring the degree of distress causes by OC symptoms SPQ: measuring the degree of schizotypic personality SEEHAN DISABILITY SCALES (SDS): measures functional impairment in three domains (social, family and work)	—

Measure

Time frame

Changes on following rating scales: CGI: clinical global impression scale BABS: Brown assessment of beliefs scale HDRS: Hamilton depression rating scale HAS: Hamilton anxiety rating scale PADUA INVENTORY: measuring the degree of distress causes by OC symptoms SPQ: measuring the degree of schizotypic personality SEEHAN DISABILITY SCALES (SDS): measures functional impairment in three domains (social, family and work)

—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)